These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 27780968)

  • 1. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.
    Griffiths R; Mikhael J; Gleeson M; Danese M; Dreyling M
    Blood; 2011 Nov; 118(18):4808-16. PubMed ID: 21873544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma].
    Cao YW; Zheng Z; Xu PP; Cheng S; Wang L; Qian Y; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):415-419. PubMed ID: 34218585
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting the intratumor heterogeneity in PMBL.
    Ritz O; Möller P; Ushmorov A
    Cell Cycle; 2014; 13(15):2317-8. PubMed ID: 25483178
    [No Abstract]   [Full Text] [Related]  

  • 4. Radioimmunotherapy in mantle cell lymphoma.
    Skarbnik AP; Smith MR
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):201-10. PubMed ID: 22687456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.
    Krishnan AY; Palmer J; Nademanee AP; Chen R; Popplewell LL; Tsai NC; Sanchez JF; Simpson J; Spielberger R; Yamauchi D; Forman SJ
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):922-929. PubMed ID: 28267593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using
    Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials.
    Rondon A; Rouanet J; Degoul F
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry.
    Hohloch K; Windemuth-Kieselbach C; Zinzani PL; Cacchione R; Jurczak W; Suh C; Trümper L; Scholz CW
    Ann Hematol; 2020 May; 99(5):1073-1079. PubMed ID: 32125469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.
    Ye H; Desai A; Huang S; Jung D; Champlin R; Zeng D; Yan F; Nomie K; Romaguera J; Ahmed M; Wang ML
    J Exp Clin Cancer Res; 2018 Jul; 37(1):150. PubMed ID: 30005678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline Treatment for Older Patients with Mantle Cell Lymphoma.
    Ye H; Desai A; Zeng D; Romaguera J; Wang ML
    Oncologist; 2018 Nov; 23(11):1337-1348. PubMed ID: 29895632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.
    Smith MR; Li H; Gordon L; Gascoyne RD; Paietta E; Forero-Torres A; Kahl BS; Advani R; Hong F; Horning SJ
    J Clin Oncol; 2012 Sep; 30(25):3119-26. PubMed ID: 22851557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibody therapy in hematology and oncology - part 1].
    Kneba M; Schrader C; Köhne H
    Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the optimal initial management of the older MCL patient?
    Kluin-Nelemans JC; Doorduijn JK
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):99-104. PubMed ID: 29452672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by
    Smith MR; Hong F; Li H; Gordon LI; Gascoyne RD; Paietta EM; Advani RH; Forero-Torres A; Horning SJ; Kahl BS
    Leukemia; 2017 Feb; 31(2):517-519. PubMed ID: 27780968
    [No Abstract]   [Full Text] [Related]  

  • 17. 90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?
    Mondello P; Steiner N; Willenbacher W; Arrigo C; Cuzzocrea S; Pitini V; Mian M
    Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):82-8. PubMed ID: 26702476
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.